• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

IIICr期无宫旁浸润宫颈癌根治性子宫切除术与同步放化疗的肿瘤学结局及并发症发生率比较

Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiotherapy in stage IIICr cervical cancer without parametrial invasion.

作者信息

Yoon Hee Yeun, Kim Jong Mi, Jeong Yoon Young, Lee Yoon Hee, Kim Min Ju, Choi Yoon Seok, Ryu Jung Min, Chong Gun Oh

机构信息

Department of Obstetrics and Gynecology, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, Republic of Korea.

Department of Obstetrics and Gynecology, Kyungpook National University Chilgok Hospital, 807 Hogukno, Buk-Gu, Daegu, 41404, Republic of Korea.

出版信息

BMC Cancer. 2025 Apr 30;25(1):811. doi: 10.1186/s12885-025-14196-8.

DOI:10.1186/s12885-025-14196-8
PMID:40307765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12044840/
Abstract

BACKGROUND

This study aimed to compare oncological outcomes and complication rates between radical hysterectomy (RH) and concurrent chemoradiotherapy (CCRT) in patients with stage IIICr cervical cancer without parametrial invasion, based on differing treatment protocols at two institutions.

METHODS

A total of 106 patients with biopsy-confirmed cervical cancer and lymph node metastasis detected on pretreatment imaging, but without evidence of parametrial invasion, were enrolled. Of these, 55 patients underwent RH, while 51 patients received CCRT. Oncological outcomes, complication rates, and recurrence patterns were analyzed and compared between the two groups.

RESULTS

At a median follow-up of 62 months (range, 3-220 months), there were no statistically significant differences in disease-free survival or overall survival between the RH and CCRT groups (p = 0.7788 and p = 0.8757, respectively). However, the incidence of overall complications was significantly higher in the RH group compared to the CCRT group (54.5% vs. 19.6%, p < 0.0001). The RH group also demonstrated a significantly greater frequency of major complications (Clavien-Dindo grade III/IV: 23.6% vs. 3.9%, p < 0.0001). Patterns of recurrence differed between the groups: the RH group exhibited a higher rate of distant metastases (56.2% vs. 16.3%), whereas the CCRT group showed a higher incidence of local recurrence (64.3% vs. 25.0%, p = 0.026).

CONCLUSION

There were no significant differences in disease-free or overall survival between patients treated with RH and those treated with CCRT. However, RH was associated with a significantly higher rate of complications. Given these findings, CCRT may represent a more favorable treatment option for patients with stage IIICr cervical cancer without parametrial invasion.

摘要

背景

本研究旨在比较两家机构基于不同治疗方案,对无宫旁浸润的IIICr期宫颈癌患者行根治性子宫切除术(RH)与同步放化疗(CCRT)后的肿瘤学结局及并发症发生率。

方法

共纳入106例经活检确诊为宫颈癌且在治疗前影像学检查发现有淋巴结转移但无宫旁浸润证据的患者。其中,55例行RH,51例接受CCRT。分析并比较两组的肿瘤学结局、并发症发生率及复发模式。

结果

中位随访62个月(范围3 - 220个月),RH组与CCRT组的无病生存率或总生存率无统计学显著差异(分别为p = 0.7788和p = 0.8757)。然而,RH组的总体并发症发生率显著高于CCRT组(54.5%对19.6%,p < 0.0001)。RH组的严重并发症发生率也显著更高(Clavien - Dindo分级III/IV级:23.6%对3.9%,p < 0.0001)。两组的复发模式不同:RH组远处转移率较高(56.2%对16.3%),而CCRT组局部复发发生率较高(64.3%对25.0%,p = 0.026)。

结论

接受RH治疗的患者与接受CCRT治疗的患者在无病生存率或总生存率方面无显著差异。然而,RH的并发症发生率显著更高。基于这些发现,对于无宫旁浸润的IIICr期宫颈癌患者,CCRT可能是更有利的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf2f/12044840/c518ddac93d4/12885_2025_14196_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf2f/12044840/c518ddac93d4/12885_2025_14196_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf2f/12044840/c518ddac93d4/12885_2025_14196_Fig1_HTML.jpg

相似文献

1
Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiotherapy in stage IIICr cervical cancer without parametrial invasion.IIICr期无宫旁浸润宫颈癌根治性子宫切除术与同步放化疗的肿瘤学结局及并发症发生率比较
BMC Cancer. 2025 Apr 30;25(1):811. doi: 10.1186/s12885-025-14196-8.
2
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.根治性子宫切除术及辅助放疗或放化疗治疗宫颈腺癌或腺鳞癌的临床行为和结局。
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):420-7. doi: 10.1016/j.ijrobp.2011.12.013. Epub 2012 Feb 24.
3
Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.根治性子宫切除术和系统淋巴结清扫术后高危宫颈癌的辅助化疗与同期放化疗比较。
Int J Clin Oncol. 2016 Aug;21(4):741-747. doi: 10.1007/s10147-016-0955-3. Epub 2016 Feb 8.
4
[Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].[术后同步放化疗对具有中危因素的早期宫颈癌患者的疗效分析]
Zhonghua Zhong Liu Za Zhi. 2018 Jun 23;40(6):462-466. doi: 10.3760/cma.j.issn.0253-3766.2018.06.012.
5
Comparison of outcomes between early-stage cervical cancer patients without high-risk factors undergoing adjuvant concurrent chemoradiotherapy and radiotherapy alone after radical surgery.早期宫颈癌患者无高危因素行根治术后单纯放疗与辅助同步放化疗的疗效比较。
BMC Cancer. 2024 Apr 30;24(1):548. doi: 10.1186/s12885-024-12284-9.
6
[Long-term oncological outcomes after laparoscopic versus abdominal radical hysterectomy in stage I a2- II a2 cervical cancer: a matched cohort study].[I a2-II a2期宫颈癌腹腔镜与开腹根治性子宫切除术后的长期肿瘤学结局:一项配对队列研究]
Zhonghua Fu Chan Ke Za Zhi. 2015 Dec;50(12):894-901.
7
Postoperative adjuvant therapy for stage IA-IIA cervical adenocarcinoma (FIGO 2018) with one intermediate-risk factor: a multicentre retrospective cohort study of 63,926 cases.对具有一个中危因素的IA-IIA期宫颈腺癌(国际妇产科联盟2018年分期)的术后辅助治疗:一项对63926例病例的多中心回顾性队列研究
World J Surg Oncol. 2025 Mar 14;23(1):87. doi: 10.1186/s12957-025-03739-9.
8
Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy.与根治性手术 +/- 新辅助化疗相比,明确的放化疗是 FIGO 分期 IB2 宫颈癌的一种有能力的治疗选择。
J Formos Med Assoc. 2019 Jan;118(1 Pt 1):99-108. doi: 10.1016/j.jfma.2018.01.015. Epub 2018 Feb 21.
9
Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.淋巴结阳性临床分期IB-IIB期宫颈癌辅助治疗的比较:全身化疗与盆腔放疗。
Int J Cancer. 2017 Sep 1;141(5):1042-1051. doi: 10.1002/ijc.30793. Epub 2017 Jun 8.
10
Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.2003年至2012年国际妇产科联盟IIb期宫颈癌的治疗结果:治疗与预后评估:一项回顾性研究
Int J Gynecol Cancer. 2015 Jun;25(5):910-8. doi: 10.1097/IGC.0000000000000430.

本文引用的文献

1
Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique.机器人前列腺切除术时的盆腔淋巴结扩大清扫术:顺行法与逆行法。
BMC Urol. 2024 Mar 21;24(1):64. doi: 10.1186/s12894-024-01448-1.
2
A comparison of concurrent chemoradiotherapy and radical surgery in patients with specific locally advanced cervical cancer (stage IB3, IIA2, IIICr): trial protocol for a randomized controlled study (C-CRAL trial).特定局部晚期宫颈癌(IB3 期、IIA2 期、IIICr 期)患者同期放化疗与根治性手术的比较:一项随机对照研究(C-CRAL 试验)的试验方案。
J Gynecol Oncol. 2023 Sep;34(5):e64. doi: 10.3802/jgo.2023.34.e64. Epub 2023 Jun 20.
3
Rationality of FIGO 2018 IIIC restaging of cervical cancer according to local tumor size: A cohort study.
FIGO 2018 ⅡIC 期宫颈癌局部肿瘤大小再分期的合理性:一项队列研究。
Acta Obstet Gynecol Scand. 2023 Aug;102(8):1045-1052. doi: 10.1111/aogs.14612. Epub 2023 Jun 20.
4
Comparison of Oncologic Outcomes between Radical Hysterectomy and Primary Concurrent Chemoradiotherapy in Women with Bulky IB and IIA Cervical Cancer under Risk Stratification.风险分层下,IB期和IIA期巨块型宫颈癌患者行根治性子宫切除术与同期放化疗的肿瘤学结局比较
Cancers (Basel). 2023 Jun 2;15(11):3034. doi: 10.3390/cancers15113034.
5
Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer.FIGO 分期 IIIC1 期宫颈癌患者的宫旁侵犯与生存降低。
J Gynecol Oncol. 2023 Jul;34(4):e46. doi: 10.3802/jgo.2023.34.e46. Epub 2023 Mar 13.
6
The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).宫颈癌患者盆腔和/或腹主动脉旁淋巴结转移的预后价值;国际妇产科联盟(FIGO)新分类(IIIC期)的影响。
Gynecol Oncol. 2023 Apr;171:9-14. doi: 10.1016/j.ygyno.2023.01.023. Epub 2023 Feb 16.
7
Complications of radical hysterectomy with pelvic lymph node dissection for cervical cancer: a 10-year single-centre clinical observational study.根治性子宫切除术加盆腔淋巴结清扫术治疗宫颈癌的并发症:一项 10 年单中心临床观察研究。
BMC Cancer. 2022 Dec 8;22(1):1286. doi: 10.1186/s12885-022-10395-9.
8
Tumor histology is an independent prognostic factor in locally advanced cervical carcinoma: A retrospective study.肿瘤组织学是局部晚期宫颈癌的独立预后因素:一项回顾性研究。
BMC Cancer. 2022 Apr 13;22(1):401. doi: 10.1186/s12885-022-09506-3.
9
Prognostic value of the 2018 FIGO staging system for cervical cancer.2018 年 FIGO 分期系统对宫颈癌的预后价值。
Gynecol Oncol. 2022 Jun;165(3):506-513. doi: 10.1016/j.ygyno.2022.02.017. Epub 2022 Mar 26.
10
Para-aortic lymph node involvement in cervical cancer: Implications for staging, outcome and treatment.宫颈癌的腹主动脉旁淋巴结累及:对分期、预后和治疗的影响。
Indian J Med Res. 2021 Aug;154(2):267-272. doi: 10.4103/ijmr.IJMR_4183_20.